Gilead Sciences (GILD) : Parkwood added new position in Gilead Sciences during the most recent quarter end. The investment management firm now holds 81,943 shares of Gilead Sciences which is valued at $7,092,167 , the company said in a statement filed on Jul 22, 2016 with the SEC.Gilead Sciences makes up approximately 1.16% of Parkwood’s portfolio.
Other Hedge Funds, Including , Bender Robert Associates reduced its stake in GILD by selling 1,477 shares or 1.46% in the most recent quarter. The Hedge Fund company now holds 100,020 shares of GILD which is valued at $8,656,731. Gilead Sciences makes up approx 5.78% of Bender Robert Associates’s portfolio.Charter Trust Co boosted its stake in GILD in the latest quarter, The investment management firm added 543 additional shares and now holds a total of 13,283 shares of Gilead Sciences which is valued at $1,151,105. Gilead Sciences makes up approx 0.13% of Charter Trust Co’s portfolio.V Wealth Managementllc boosted its stake in GILD in the latest quarter, The investment management firm added 555 additional shares and now holds a total of 27,015 shares of Gilead Sciences which is valued at $2,341,120. Gilead Sciences makes up approx 1.85% of V Wealth Managementllc’s portfolio.Exxonmobil Investment Management Inc Tx boosted its stake in GILD in the latest quarter, The investment management firm added 11,948 additional shares and now holds a total of 344,742 shares of Gilead Sciences which is valued at $29,837,420. Gilead Sciences makes up approx 0.62% of Exxonmobil Investment Management Inc Tx’s portfolio.
Gilead Sciences closed down -1.77 points or -2.18% at $79.47 with 1,94,65,672 shares getting traded on Friday. Post opening the session at $80.6, the shares hit an intraday low of $79.37 and an intraday high of $80.84 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.
Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .Gilead Sciences was Downgraded by Needham to ” Hold” on Jul 26, 2016.
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.